SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3561 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1310<i>I take your point, but I think that you may be reading too much into a DewDiligence_on_SI-8/3/2007
1309<i>Is lucentis being studied once per 8 weeks? That's the second trap DewDiligence_on_SI-8/3/2007
1308I take your point, but I think that you may be reading too much into a single phnigel bates-8/3/2007
1307It's likely a secondary endpoint. I think number one for any pivotal trrkrw-8/3/2007
1306<i>But I don't understand your point. A lot of trials are non inferiorDewDiligence_on_SI-8/3/2007
1305OK boss. I don't think regn/bayer are running the trial in hopes of being merkrw-8/3/2007
1304<i>As Nigel pointed out you misread the pr.</i> No, I did not. <DewDiligence_on_SI-8/3/2007
1303In ophthalmology, “maintained or improved vision” and “maintained vision” are twDewDiligence_on_SI-8/3/2007
1302As Nigel pointed out you misread the pr. Is there enough info out there on trarkrw-8/3/2007
1301>>The primary endpoint of the study is the proportion of patients treated nigel bates-8/3/2007
1300It’s revealing that the primary endpoint is non-inferiority to Lucentis on <iDewDiligence_on_SI-8/3/2007
1299Regeneron and Bayer HealthCare Initiate Phase 3 Global Development Program For Vscaram(o)uche-8/3/2007
1298Finally, low level food processing ing. is out. bizjournals.com New general maMiljenko Zuanic-7/30/2007
1297TargeGen Initiates Phase-2 Trial of AMD Eye Drop: siliconinvestor.comDewDiligence_on_SI-7/30/2007
1296You are right. I totally forgot about that part. I would think the product in qkenhott-7/20/2007
1295wasn't clear to me from discussions. has RGN made public decision on thesbio_kruncher-7/20/2007
1294NVS had the IL-1beta in development when they decided to part ways with the REGNkenhott-7/20/2007
1293I think that they have reasonable shot for ovarian/ascite. Safety is in line wiMiljenko Zuanic-7/19/2007
1292Do you have an opinion about the ASCO data, especially the side effect discussiokenhott-7/19/2007
1291Ouch! Don't have to pay regn 50%? :-)rkrw-7/19/2007
1290Novartis, after rejecting IL-1 Trap, is going with their IL-1 antibody after theMiljenko Zuanic-7/18/2007
1289AMD competitor begins phase-3: investorshub.comDewDiligence_on_SI-7/11/2007
1288Regeneron Submits Biologics License Application to U.S. FDA for IL-1 Trap (Rilonnigel bates-6/8/2007
1287Thanks for the replies.kenhott-6/6/2007
1286Good deal on your timely exit and trusting your instincts. Maybe the stock hadrkrw-6/5/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News